Apple
AAPL
Taylor Morrison Home
TMHC
D.R. Horton
DHI
4
Petroleo Brasileiro SA Petrobras
PBR
5
Vale SA
VALE
US Stock MarketDetailed Quotes
URGN UroGen Pharma Ltd
- 11.450
- -0.070-0.61%
Close Mar 27 16:00 ET
- 11.450
- 0.0000.00%
Post 16:36 ET
527.78MMarket Cap-3.87P/E (TTM)
11.913High11.130Low729.54KVolume11.590Open11.520Pre Close8.32MTurnover1.97%Turnover RatioLossP/E (Static)46.09MShares20.70052wk High-59.95P/B423.57MFloat Cap9.03052wk Low--Dividend TTM36.99MShs Float69.568Historical High--Div YieldTTM6.80%Amplitude4.850Historical Low11.409Avg Price1Lot Size
UroGen Pharma Ltd News
Raymond James Initiates UroGen Pharma Ltd(URGN.US) With Buy Rating, Announces Target Price $36
H.C. Wainwright Initiates UroGen Pharma Ltd(URGN.US) With Buy Rating, Announces Target Price $55
UroGen Pharma Price Target Cut to $55.00/Share From $64.00 by HC Wainwright & Co.
UroGen Pharma Ltd | 10-K: FY2024 Annual Report
TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $35
Earnings Call Summary | UroGen Pharma Ltd(URGN.US) Q4 2024 Earnings Conference
Urogen Pharma Outlines $1B Revenue Potential for UGN-102 With June 2025 Launch Target
UROGEN PHARMA Earnings Results: $URGN Reports Quarterly Earnings
UroGen Pharma Ltd | 8-K: UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102
UroGen Pharma Q4 2024 GAAP EPS $(0.80) Misses $(0.68) Estimate, Sales $24.57M Miss $25.63M Estimate
UroGen Pharma 4Q Loss $37.5M >URGN
UroGen Pharma 4Q Rev $24.6M >URGN
Earnings Scheduled For March 10, 2025
UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% From the Phase 3 ENVISION Trial of UGN-102
UROGEN PHARMA Earnings Preview: Recent $URGN Insider Trading, Hedge Fund Activity, and More
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Earnings Preview: URGN to Report Financial Results Pre-market on March 10
Press Release: UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025
When Can We Expect A Profit From UroGen Pharma Ltd. (NASDAQ:URGN)?
UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call